Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of a recombinant human cell line protein in the preparation of drugs for preventing or treating pulmonary fibrosis

A pulmonary fibrosis and cell line technology, which can be used in drug combinations, respiratory diseases, peptide/protein components, etc., can solve problems such as lack of rhCygb research reports, and achieve protection from oxidative stress damage, broad market prospects, good Social and economic benefits

Active Publication Date: 2020-08-04
SOUTHERN MEDICAL UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that recombinant human cytoglobin (rhCygb) is used in the treatment of hyperlipidemia, atherosclerosis, fatty liver, liver cirrhosis and other diseases, but there is no evidence that rhCygb is related to idiopathic pulmonary fibrosis, especially When the etiology of idiopathic pulmonary fibrosis is still unclear, there is also a lack of research reports on rhCygb and the pathogenesis of IPF

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of a recombinant human cell line protein in the preparation of drugs for preventing or treating pulmonary fibrosis
  • Use of a recombinant human cell line protein in the preparation of drugs for preventing or treating pulmonary fibrosis
  • Use of a recombinant human cell line protein in the preparation of drugs for preventing or treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1 idiopathic pulmonary fibrosis modeling

[0021] 1. Experimental animals

[0022] Forty-five SPF grade adult male SD rats were purchased from Guangdong Medical Experimental Animal Center. The rats weighed 180-220 g, with an average of (198.35±19.28) g, and were randomly divided into two groups: 11 rats in the control group and 34 rats in the model group. Common feed was given under the condition of room temperature of 24°C and humidity of 78%.

[0023] 2. Main reagents and instruments

[0024] Bleomycin hydrochloride for injection (BLM, Nippon Kayaku Co., Ltd., 5mg / kg), batch number 430312

[0025] 2% pentobarbital solution (50mg / kg), batch number 69020100

[0026] 16-layer spiral, model SomAToM Emotion CT, Siemens AG, Germany

[0027] Serum fiber four index detection reagents were purchased from Shenzhen New Industry Biomedical Engineering Co., Ltd., batch number 2013992021

[0028] Dexamethasone Sodium Phosphate Injection (Shenyang Yangguang Pharmace...

Embodiment 2

[0068] Example 2 Grouping and treatment of idiopathic pulmonary fibrosis

[0069] 1. Experimental grouping

[0070] On the 2nd day after the successful modeling was confirmed by the first CT scan, that is, on the 8th day after the modeling, the model rats were randomly divided into a model group (group b, n=11), a dexamethasone treatment group (group c, n =11) and rhCygb group (group d, n=12). Group b was given normal feeding without any drug intervention; group c was given subcutaneous injection of dexamethasone injection 3 mg / kg daily from the 8th day after model establishment; group d was given subcutaneous injection of rhCygbd ​​protein 4 mg daily from the 8th day after model establishment / kg (select CN 104096218 A patent to disclose recombinant human cell globin). On the 28th day and 56th day after the modeling, blood was collected from the tail vein of the rats to detect the four indicators of fibrosis. On the 56th day after the modeling, the second lung CT scan was p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of cell strain protein in preparing medicines for preventing or treating pulmonary fibrosis diseases of mammals. The cell strain protein is human cell strain protein, and the application refers to the application in preventing or treating idiopathic pulmonary fibrosis diseases. The recombinant human Cygb provided by the invention can treat idiopathic pulmonaryfibrosis surprisingly. Therefore, the invention discloses the application of the recombinant human cell strain protein (rhCygb) in serving as a genetically engineered medicine for treating pulmonaryfibrosis, and good social benefits and economic benefits can be brought.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and in particular relates to the use of recombinant human cell strain protein for treating pulmonary fibrosis. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic interstitial lung disease with unknown etiology and characterized by pathological changes of common interstitial pneumonia. The prognosis of IPF is poor, the median survival period after diagnosis is 3 years, and the 5-year survival rate is close to 20%, indicating that the mortality rate of IPF is higher than that of some cancers. At present, the pathogenesis of IPF is not yet clear, and there are many pathogenesis theories, all of which explain the mechanism of IPF from different ways. At present, the more common view is that the mechanism of IPF is roughly as follows: continuous or repeated harmful stimulation causes alveolar epithelial cells (alveolar epithelial cells, AECs) damage or increased ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/17A61P11/00
Inventor 董文其林忠顺李珍王萍魏威
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com